Natalia Anchipolovsky, DO
Endocrinology, Diabetes & Metabolism · Hackensack, NJNPI 1982725024
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,200 of the $39,517 with a category attached, or 73.9%. AstraZeneca accounts for 81.1% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2019 at $11,374 and has fallen 83.9% since, to $1,832 in 2025. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 426 payments — averaging $92.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$32K
- Amgen$1K
- Lilly USA, LLC$1K
- Novo Nordisk$701
- Corcept Therapeutics$599
- AbbVie$438
- plus $3K from 36 others
What the payments were for
- Consulting fees$9302%
- Speaking & faculty fees$29,20074%
- Travel & lodging$2141%
- Food & beverage$8,76622%
- Education$2781%
- Gifts$590%
- Other$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,517 in reported general payments places this provider in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 430 | $703,730 |
| MounjaroTirzepatide | 448 | $592,655 |
| TrulicityDulaglutide | 164 | $264,692 |
| Somatuline DepotLanreotide Acetate | 26 | $214,175 |
| JardianceEmpagliflozin | 174 | $198,848 |
| FarxigaDapagliflozin Propanediol | 152 | $173,743 |
| RybelsusSemaglutide | 78 | $142,951 |
| Tresiba Flextouch U-100Insulin Degludec | 208 | $121,846 |
| KorlymMifepristone | 11 | $121,020 |
| ProliaDenosumab | 64 | $105,915 |
| Xigduo XrDapaglifloz Propaned/Metformin | 65 | $93,210 |
| JanuviaSitagliptin Phosphate | 71 | $77,753 |
| TradjentaLinagliptin | 54 | $59,994 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 41 | $57,668 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 67 | $47,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,019 | $857,346612 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $701 | $856,623528 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $177 | $301,155256 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $14 | $214,17526 claims |
| AstraZenecaFarxiga | $32,052 | $173,743152 claims |
| MerckJanuvia, Janumet, Janumet Xr | $28 | $141,833129 claims |
| Corcept TherapeuticsKorlym | $599 | $121,02011 claims |
| AmgenProlia | $1,482 | $105,91564 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $407 | $17,70415 claims |
| AbbVieSynthroid | $438 | $16,503216 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $111 | $8,777744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Hackensack
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.